$280 | Single User
$560 | Site License
$840 | Global License

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

Published by La Merie: 01 May 2016 | 675 | In Stock

Introduction

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update


This Competitive Intelligence report about Biosimilar and Biosuperior Anti-EGF-R Antibodies updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting epithelial growth factor receptor (EGF-R) in comparison with originator anti-EGF-R antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.


The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:



  • Drug Codes,

  • Target / Mechanism of Action,

  • Class of Compound,

  • Company,

  • Product Category,

  • Indication,

  • R&D Stage and

  • additional comments with a hyperlink leading to the source of information.


About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Table of Contents
for Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

  • Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update

    Table of Contents

    1.         Sales of Anti-EGF-R Antibodies

    2.         Originator Anti-EGF-R Antibodies

    Erbitux Approved Indications & Pipeline

    Vectibix Approved Indications & Pipeline

    Nimotuzumab Approved Indications & Pipeline

    Portrazza Approved Indications & Pipeline

    3.         Biosuperior Anti-EGF-R Antibodies

    3rd Generation Anti-EGF-R Antibodies

    Bispecific Anti-EGF-R Antibodies

    Anti-EGF-R Antibody Drug Conjugates

    4.         Biosimilar Anti-EGF-R Antibodies

    Erbitux Biosimilar Antibodies:

    -           Developments in Regulated Markets

    -           Developments in Less Regulated Markets

    5.         Corporate Anti-EGF-R Biosimilar & Biosuperior Antibody Pipelines

Additional Details

Publisher

La Merie

Publisher Information

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Reference

675 | LMCA0126

Number of Pages

56

Report Format

PDF

La Merie Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other Diseases
Competitor Analysis: Bispecific Antibodies for Cancer, Inflammatory & Other DiseasesThis Compet...
01 Jun 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-TNF Antibodies – 2016 Update Humira, Enbrel a...
01 May 2016 by La Merie USD $560 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update This Competitiv...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-CD20 Antibodies – 2016 UpdateTable of Contents...
01 May 2016 by La Merie USD $335 More Info
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 UpdateThis Competitive...
01 May 2016 by La Merie USD $280 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: CD19-Targeted Therapeutics - 2016 Update
Competitor Analysis: CD19-Targeted Therapeutics – 2016 Update This Competitive Intelligence report...
01 Apr 2016 by La Merie USD $350 More Info
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) family
Competitor Analysis: Inhibitors of the bromodomain and extra-terminal domain (BET) familyThe Compet...
17 Jan 2016 by La Merie USD $225 More Info
Physician Views: And then there were two – will AbbVie's 3-DA regimen prove a compelling competitor to Gilead's Harvoni?
Scope Later this month, the FDA is expected to approve AbbVie's oral '3-DA' product - comprising Vie...
11 Dec 2014 by FirstWord Pharma USD $695 More Info
Physician Views: A Victoza competitor in waiting? – Can Eli Lilly's dulaglutide make an impact in the GLP-1 agonist market?
Scope Last week, Eli Lilly confirmed that in the head-to-head AWARD-6 study its experimental GLP-1 a...
05 Mar 2014 by FirstWord Pharma USD $695 More Info

This report is published by La Merie

La Merie Publishing is an independent business information provider for the biotechnology and pharmaceutical industry. We publish reports, offer R&D database access, and provide consulting in pharmacology and biotechnology. Our products and subscription services are commercialized via our associated biotech portal PipelineReview.com.

Download Free Report Summary PDF

Competitor Analysis: Biosimilar and Biosuperior Anti-EGF-R Antibodies - 2016 Update | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data